A Multi-center, Double-blind, Flexible-dose Efficacy Trial With Org 25935 Versus Placebo as add-on Therapy in Subjects With Predominant, Persistent Negative Symptoms of Schizophrenia Treated With a Stable Dose of a Second Generation Antipsychotic (GIANT)

Trial Profile

A Multi-center, Double-blind, Flexible-dose Efficacy Trial With Org 25935 Versus Placebo as add-on Therapy in Subjects With Predominant, Persistent Negative Symptoms of Schizophrenia Treated With a Stable Dose of a Second Generation Antipsychotic (GIANT)

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2016

At a glance

  • Drugs ORG 25935 (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Acronyms GIANT
  • Sponsors Organon; Schering-Plough
  • Most Recent Events

    • 12 Feb 2014 Primary endpoint 'Schedule-for-Assessment-of-Negative-Symptoms' has not been met.
    • 12 Feb 2014 Results published in the Journal of Clinical Psychopharmacology.
    • 28 Jun 2012 Additional trial location (Austria) added as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top